Slow acetylator genotype of N-acetyl transferase2 (NAT2) is associated with increased susceptibility to gallbladder cancer: The cancer risk not modulated by gallstone disease

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 91-96

  Pandey, Sachchida Nand ^a   Modi, Dinesh Raj ^b   Choudhuri, Gourdas ^a   Mittal, Balraj ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF LUCKNOW   (India)

Author keywords

Gallbladder cancer; Gallstone disease; Genetic polymorphism; Genetic susceptibility; N acetyl transferase; Slow acetylator; Xenobiotics

Indexed keywords

ACYLTRANSFERASE; ACYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHOLELITHIASIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GALLBLADDER CANCER; GALLSTONE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 33847129678     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3554     Document Type: Article

References (36)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4:167-76.
2. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51:349-64.
3. Doll R, Peto R. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66:1191-208.
4. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25:27-65.
5. Kowalewski K, Todd EF. Carcinoma of the gallbladder induced in hamsters by insertion of cholesterol pellets and feeding dimethylnitrosamine. Proc Soc Exp Biol Med 1971; 136:482-86.
6. Garte S, Gaspari L, Alexandrie A, Ambrosone C, Autrup H, Autrup HJ, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Omo MD, Dolzan V, Dresler CM, Anthony Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Marchand LC, Lechner MC, van Lieshout EMM, London S, Manni JJ, Maugard CM, Morita S, Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WHM, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, cker IS, Sugimura H, Figueras JT, Vineis P, Yu MC, Taioli E. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10:1239-48.
7. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29-42.
8. Hein DW. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77.
9. Degott C, Feldmann G, Larrey Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A. Drug induced prolonged cholestasis in adults: A histological semi quantitative demonstrating progressive ductopenia. Hepatology 1992; 15:244-51.
10. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
11. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-92.
12. Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow WH, Zheng W, Hein DW, Garcia-Closas M. Impact of misclassification in genotype-exposure interaction studies: Example of Nacetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1543-6
13. Arylamine N-acetyltransferase nomenclature committee. Arylamine N Acetyltransferase (NAT) nomenclature. (Available at www.louisville.edu/ medschool/pharmacology/NAT.html (accessed 14 March, 2006)).
14. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15:273-80.
15. Lakehal F, Wendum D, Barbu V, Becquemont L, Poupon R, Balladur P, Hannoun L, Ballet F, Beaune PH, Housset C. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium. Hepatology 1999; 30:1498-506.
16. Perera FP. Environment and cancer: Who are susceptible? Science 1997; 278:1068-73.
17. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine Nacetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39:184-91.
18. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
19. Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem 1990; 265:12757-60.
20. Hickman D, Sim E. N-acetyltransferase polymorphism: Comparison of phenotype and genotype in humans. Biochem Pharmacol 1991; 42:1007-14.
21. Costa S, Medeiros R, Vasconcelos A, Pinto D, Lopes C. A slow acetylator genotype associated with an increased risk of advanced cervical cancer. J Cancer Res Clin Oncol 2002; 128:678-82.
22. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Castaño-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Torà M, Fernández F, Real FX, Rothman N. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366:649-59.
23. Agundez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benitez J. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996; 6:501-12.
24. Shibuta J, Eto T, Kataoka A, Inoue H, Ueo H, Suzuki T, Barnard GF, Mori M. Genetic polymorphism of N-acetyltransferase 2 in patients with esophageal cancer. Am J Gastroenterol 2001; 96:3419-24.
25. Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, Augustsson K, Wolf CR, Bishop DT, Forman D. Colorectal cancer stusy group: Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carcinogenesis 2003; 24:275-82
26. Lan Q, Rothman N, Chow WH, Lissowska J, Doll MA, Xiao GH, Zatonski W, Hein DW. No Apparent Association between NAT1 and NAT2 Genotypes and Risk of Stomach. Cancer Epidemiol Biomarkers Prev 2003; 12:384-86.
27. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991; 88:5237-41.
28. Zang Y, Zhao S, Doll MA, States J, Christopher H, Hein D. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 2004; 14:717-23.
29. Willey JC, Coy YE, Brolly C, Utell MJ, Frampton MW, Hammersley J, Thilly WG, Olson D, Cairns K. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. Am J Respir Cell Mol Biol 1996; 14:262-71.
30. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: An analysis and implication for research. Carcinogenesis 1995; 16:39-52.
31. Robbana-Barnats S, Rabache M, Rilalland E. Heterocyclic amines: Occurrence and prevention in cooked food. Environ Health Perspect 1996; 104:280-8.
32. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1988; 14:1633-8.
33. Hiroven A. Polymorphic NATs and cancer predisposition. In: Vineis P, Caporaso N, Cuzick J, Lang M, Malats N, Boffetta P, eds. Genetic susceptibility to cancer: Metabolic polymorphisms. Lyon: IARC Scientific Publication, 1999:251-70.
34. Yen S, Hsieh CC, MacMahon B. Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. Cancer 1987; 59:2112.
35. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, Bueno de Mesquita HB, Ghadirian P, Jain M, Przewozniak K, Baghurst P, Moerman CJ, Simard A, Howe GR, McMichael AJ, Hsieh CC, Walker AM. Epidemiologic aspects of gallbladder cancer: A case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst 1997; 89:1132-8.
36. Mumford JL, Li X, Hu F, Lu XB, Chuang JC. Human exposure and dosimetry of polycyclic aromatic hydrocarbons in urine from Xuan Wei, China with high lung cancer mortality associated with exposure to unvented coal smoke. Carcinogenesis 1995; 16:30-1.